Cantor Fitzgerald Comments on Rezolute FY2025 Earnings

Rezolute, Inc. (NASDAQ:RZLT) – Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Rezolute in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will post earnings of ($0.97) per share for the year. The consensus estimate for Rezolute’s current full-year earnings is ($0.99) per share.

Rezolute (NASDAQ:RZLT) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.13.

Several other equities research analysts have also recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price target on shares of Rezolute in a report on Friday, November 8th. Wedbush restated an “outperform” rating and issued a $112.00 target price on shares of Rezolute in a report on Monday, November 4th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $24.13.

Rezolute Trading Up 3.7 %

RZLT stock opened at $4.99 on Thursday. The company has a market cap of $289.12 million, a price-to-earnings ratio of -3.93 and a beta of 1.08. The firm has a 50-day moving average of $4.89 and a two-hundred day moving average of $4.85. Rezolute has a 12 month low of $0.92 and a 12 month high of $6.19.

Institutional Investors Weigh In On Rezolute

Institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC increased its holdings in Rezolute by 39.0% in the 3rd quarter. Geode Capital Management LLC now owns 491,601 shares of the company’s stock valued at $2,385,000 after purchasing an additional 137,905 shares during the last quarter. MML Investors Services LLC purchased a new position in shares of Rezolute during the third quarter worth $57,000. State Street Corp raised its holdings in shares of Rezolute by 11.6% in the 3rd quarter. State Street Corp now owns 125,472 shares of the company’s stock valued at $609,000 after buying an additional 13,000 shares during the period. Cubist Systematic Strategies LLC raised its holdings in shares of Rezolute by 366.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 54,237 shares of the company’s stock valued at $233,000 after buying an additional 42,597 shares during the period. Finally, Affinity Asset Advisors LLC lifted its stake in Rezolute by 15.6% during the 2nd quarter. Affinity Asset Advisors LLC now owns 1,850,000 shares of the company’s stock worth $7,955,000 after acquiring an additional 250,000 shares in the last quarter. 82.97% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Rezolute

In related news, CFO Daron Evans bought 10,000 shares of the stock in a transaction on Wednesday, December 18th. The stock was bought at an average price of $4.29 per share, with a total value of $42,900.00. Following the completion of the purchase, the chief financial officer now directly owns 150,900 shares in the company, valued at $647,361. This represents a 7.10 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 18.39% of the company’s stock.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.